Clozapine and myocarditis: A case series from the New Zealand Intensive Medicines Monitoring Programme

New Zealand Medical Journal

Volumn 121, Issue 1283, 2008, Pages 68-74

  Hill, Geraldine R ^a   Harrison Woolrych, Mira ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; AUSTRALIA; CASE STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG FATALITY; DRUG SURVEILLANCE PROGRAM; DRUG USE; FEMALE; HUMAN; INCIDENCE; MALE; MORBIDITY; MORTALITY; MYOCARDITIS; NEW ZEALAND; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; SCHIZOPHRENIA; SEX RATIO; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; FACTUAL DATABASE; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDITIS; NEW ZEALAND; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 55249117530     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews. 2000;CD000059.
2. Alvir JMJ, Lieberman JA, Safferman AZ, et al. Clozapine-Induced Agranulocytosis - Incidence and Risk Factors in the United States. N Engl J Med. 1993;329:162-7.
3. Anonymous. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry. 2005;39:1-30.
4. Vesterby A, Pedersen JH, Kaempe B, Thomsen NJ. [Sudden death during treatment with clozapine (Leponex)]. Ugeskr Laeger. 1980;142:170-1.
5. Killian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine.[see comment]. Lancet. 1999;354:1841-5.
6. Novartis. Dear Health Care Provider: Myocarditis added to Boxed Warning; 2002.
7. Coulter DM, Bate A, Meyboom RH, et al. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: Data mining study. BMJ. 2001;322:1207-9. See also BMJ Website extra for explanation of Bayesian Neural Network Analysis at http://www.bmj.com/cgi/content/ full/322/7296/1207/DC1
8. Haas SJ, Hill R, Krum H, et al. Clozapine-associated myocarditis: A review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf. 2007;30:47-57.
9. Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998;59:3-7.
10. Harrison-Woolrych M, Coulter DM. PEM in New Zealand. In: Mann RTD, Andrews EB, eds. Pharmacovigilance. Second ed. Chichester: John Wiley & Sons, Ltd; 2007:317-32.
11. Meyboom RH, Hekster YA, Egberts AC, et al. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf. 1997;17:374-89.
12. Hagg S, Spigset O, Bate A, Soderstrom TG. Myocarditis related to clozapine treatment. J Clin Psychopharmacol. 2001;21:382-8.
13. La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med. 2001;345:224-5.
14. Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol. 2005;25:32-41.
15. Devarajan S, Kutcher SP, Dursun SM. Clozapine and sudden death. Lancet. 2000;355:841;author reply 43.
16. Ronaldson K, McNeil J. A case-control study to identify risk factors for myocarditis with clozapine. http://www.ccretherapeutics.org.au/ research/clozapine/